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The  subject  of  this  thesis  work  was  prolyl  oligopeptidase  inhibitors.  The  aim was  to 
prepare a series of syntheses that would result in a number of different final products with 
basic  function.  The thesis  work was commissioned  by the  University  of  Antwerp,  the 
Department of Medicinal Chemistry. 
Prolyl oligopeptidase is a serine protease. It is specialised in hydrolysing peptide bonds 
with proteins that have a proline ring. This function is  important because it means prolyl 
oligopeptidase can participate in the degradation of neuropeptides. Many neuropeptides 
contain a proline ring because it protects them from most enzymes.
This  means  that  prolyl  oligopeptidase  might  have  an  important  role  in  neurological 
diseases. The studies have shown that there is a connection between prolyl oligopeptidase 
and learning and memory disorders such as Alzheimer’s disease. 
Therefore, the inhibitors of prolyl oligopeptidase could be a base for new drugs in treating 
these diseases. Some studies imply that the enzyme activity is increased correlating with 
the disease.  The inhibition of prolyl  oligopeptidase could be a part  of the cure for the 
disease. There has been an ongoing project at the University of Antwerp for producing 
new prolyl oligopeptidase inhibitors for a few years. In this thesis work the focus is on 
inhibitors with basic decorating substituents.
The process of producing a new inhibitor molecule takes all in all a nine-step synthesis. 
The first eight steps are for building up a scaffold and in the ninth step the decorating 
group is added. The final products are analysed by mass spectrometry, NMR and HPLC. 
All  the  desired  products  could  be produced and purified.  Unfortunately there was not 
enough time to perform testing of inhibitor activity. In that sense the work still needs to be 
continued.
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Työn  tarkoituksena  oli  valmistaa  inhibiittoreita  prolyylioligopeptidaasille. 
Prolyylioligopeptidaasi on seriiniproteaasi, joka on erikoistunut pilkkomaan pienikokoisia 
peptidejä,  joissa  on  proliinirengas.  Ihmisellä  prolyylioligopeptidaasia  esiintyy  ympäri 
kehoa, mutta erityisesti sen sijainti aivoissa on terveydelle tärkeä. Prolyylioligopeptidaasi 
on yksi niistä entsyymeistä, joka voi osallistua neuropeptidien hajoittamiseen.
Tämä ominaisuus tekee siitä tärkeän aivojen toimintaan liittyvien  sairauksien hoidossa. 
Prolyylioligopeptidaasilla  on  havaittu  yhteys  muun  muassa  Alzheimerin  tautiin  sekä 
kaksisuuntaiseen  mielialahäiriöön.  Prolyylioligopeptidaasin  toimintamekanismi  näissä 
sekä muissa sairauksissa ei  ole  vielä  täysin  selvitetty,  mutta  tutkimuksia  tehdään koko 
ajan.
Vaikka  toimintamekanismia  ei  ole  vielä  selvitetty,  on  kuitenkin  kannattavaa  ryhtyä 
etsimään  tehokkaita  inhibiittoreita  prolyylioligopeptidaasille.  Entsyymin  aktiivisuuden 
lisääntymisellä  ja  esimerkiksi  Alzheimerin  taudilla  on  havaittu  korrelaatio.  Tehokas 
inhibiittori voisi olla osana taudin hoidossa. Tätä työtä on tehty Antwerpenin yliopiston 
lääkekemian laitoksella  jo useamman vuoden ajan. Tässä opinnäytetyössä on keskitytty 
erityisesti emäksisillä ominaisuuksilla varustettujen inhibiittorien valmistukseen.
Inhibiittoreita  valmistettiin  yhteensä  viisi  kappaletta.  Koko  prosessi  oli  yhteensä 
yhdeksänvaiheinen synteesi,  jossa kahdeksan vaihetta tarvittiin rungon valmistukseen ja 
viimeisessä vaiheessa lisättiin molekyylit toisistaan erottava funktionaalinen ryhmä.
Lopputuotteet  analysoitiin  massaspektrometrillä,  NMR:llä  sekä  HPLC:llä.  Kaikkien 
suunniteltujen lopputuotteiden valmistuksessa onnistuttiin. Lopputuotteiden inhibitiotehoa 
ei ehditty kuitenkaan analysoimaan, joten siinä mielessä työtä on vielä jatkettava.
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81  INTRODUCTION
This thesis  work  was  done  at  the  Department  of  Medicinal  Chemistry  at  the 
University of Antwerp, Belgium. The aim of the study was to prepare inhibitors for 
prolyl oligopeptidase. The subject was based on the previous work that had been 
done in  the  prolyl  oligopeptidase  project.  In  this  thesis  work the focus  was on 
preparing five inhibitors that would have the same scaffold but would differ in the 
decorating substituents.
Prolyl oligopeptidase is a serine protease that is found in many places in human 
body but the localization in brain is the most interesting for the researchers. There 
are  studies  that  indicate  that  prolyl  oligopeptidase  is  somehow  related  to 
neurological  diseases.  The  studies  are  mainly  focused  on memory and learning 
disorders such as Alzheimer’s disease. The exact function of prolyl oligopeptidase 
is  yet  to  be  clarified.  The  studies  that  show  a  correlation  with  a  high  prolyl 
oligopeptidase activity and a memory disorder was the basis of this thesis work and 
reason why just inhibitors were made. If an efficient inhibitor could be prepared it 
could come a drug against these diseases. In addition, it could be used to further test 
what would happen if the prolyl oligopeptidase would be inhibited in physiology.
The synthesis was planned based on the previous projects that had been going on 
among the research group. All in all a nine-step synthesis was planned to carry out. 
The steps were somewhat similar to what had been made previously.  In the first 
eight steps the scaffold would built up and then in the last step a different basic 
decorating substituents would be added. 
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The additional  aim of the thesis  work was to  test  the inhibitory activity  of  the 
compounds. Due to time restrictions this was not done. So the exact potential for 
further drug development still remains to be examined.
10
2 THEORETICAL BACKGROUND
2.1 Prolyl oligopeptidase
Prolyl  oligopeptidase  (EC  3.4.21.26)  is  a  serine  protease.  Walter  et  al. first 
discovered it in human uterus in 1971 and it was then named prolyl endopeptidase 
(1).  When  more  information  of  functions  of  prolyl  oligopeptidase  (PO)  was 
gathered it was discovered that it hydrolyses oligopeptidases instead of proteins like 
other  endopeptidases  and  the  name  was  proposed  to  be  changed  to  prolyl 
oligopeptidase (2).  The IUBM (International Union of Biochemistry and Molecular 
Biology) recommends now the name prolyl oligopeptidase because it describes the 
enzymes functions more accurately (3). 
N
H
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O
Figure 1: Proline.
Prolyl  oligopeptidase  is  found  in  mammals,  bacteria  and  even  archaea,  only 
exception being fungi (4). It is small sized, only 80 kDa, intracellular enzyme.  Due 
to  its  localization  in  brain,  it  is  considered  to  have  a  role  in  maturation  and 
degradation of neuropeptides and peptide hormones (5).  Most peptidases are not 
able  to  take  part  on  hydrolysing  the  peptide  bond  at  proline  residues  because 
proline (Figure 1) is an imino rather than an amino acid. Proline is an amino acid 
that  has  secondary  amine  group and that  is  why it  is  called  imino  acid.  Many 
neuropeptides and peptide hormones contain one or more proline residues to protect 
then  from  enzymatic  degradation.  Proline-specific  enzymes  are  therefore  often 
required for processing such peptides. (6)
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Serine proteases are proteases that share a common serine residue at their active 
site. The prolyl oligopeptidase family is a one family among the serine proteases. In 
addition to PO this family includes for example dipeptidyl peptidase IV (DPP IV), 
acylaminoacyl  peptidase  and oligopeptidase  B.  These  proteases  are  specified  in 
hydrolysing  oligopeptides  that  are  less  than  30  amino  acids.  (4)  Prolyl 
oligopeptidase hydrolyses oligopeptides after proline residues (7). 
2.2 Prolyl oligopeptidase and diseases
According  to  recent  studies,  prolyl  oligopeptidase  might  have  a  role  in  various 
neurological conditions. Two mainly studied groups are memory disorders, such as 
Alzheimer’s disease and mental disorders like major depression and schizophrenia. 
The  function  of  prolyl  oligopeptidase  in  these  various  diseases  is  not  yet  fully 
understood.  Moreover,  the  function  varies  a  lot  between  the  different  types  of 
diseases.
Many neuropeptides contain proline and therefore it  has been proposed that  PO 
might have a role in their metabolism. Arginine vasopressin (AVP), substance P 
(SP)  and  thyrotropin-releasing  hormone  (TRH)  are  all  neuropeptides  that  are 
connected with learning and memory and they contain proline. The effect of the PO 
activity  is  however  a  complicated  matter.  There  are  studies  reporting  that  PO 
activity is enhanced in the brains of patients with Alzheimer’s disease (AD). On the 
other hand, there are also studies contradicting that result reporting that PO activity 
is reduced in AD patients. One explanation could be that PO has different role in 
different stages of AD. (8)
Recent studies have suggested that PO could participate in mood disorders. There is 
a hypothesis that PO is a regulator of inositol phosphate (InsP). Inositol depleting 
drugs (e. g. lithium) are used in the treatment of bipolar disorder (BD) and this is 
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how PO could be a part of BD. (9) There are also reports implying that there is a 
decrease of plasma PO activity in BD. The inhibition of PO has been shown to 
reverse the effect on lithium based mood stabilizer drugs. The matter is still under 
research investigating the exact mechanism and effect on BD. (10)
What can be gathered from the above mentioned is that a substantial research effort 
focusing on the role of PO and its functions in body is required. These diseases are 
just examples of the variety of theories of PO’s role in diseases. For example there 
are also theories that  PO could have a  role  in eating disorders and Parkinson’s 
disease  (11).  At  the  same  time  the  development  of  the  inhibitors  of  prolyl 
oligopeptidase  can  be  considered  a  valuable  work:  such  compounds  can  play 
important  roles  in  studying  PO's  role  in  physiology  and  in  the  future  selected 
compounds can be developed further to produce efficient drugs against PO related 
diseases.
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3 SYNTHETIC PROCESS
Most of the inhibitors that have been made this far are proline mimetics. In this 
thesis work, the lead compound was chosen to be the prolylproline motif. Proline 
has  a  cyclic  structure  that  separates  it  from other  amino  acids.  The  reason  for 
favouring proline is that prolyl oligopeptidase is a proline specified enzyme.
The aim of the syntheses was to prepare a number of end compounds that would 
share a common prolylproline-derivated scaffold, decorated with basic functional 
groups. There have been previous projects with the same scaffold but in this work, 
the goal was to add different groups with basic functions.  The reason for this is that 
basic  compounds  are  usually  protonated  at  the  physiological  pH  and  therefore 
dissolve better in water. At the same time, the choice of substituents that have pKa 
values  of  maximally  10,  can  be  expected  not  to  interfere  with  the  compounds' 
ability to enter the Central Nerve System by passive diffusion. The last step was 
done  using  CuI-catalysed  alkyne-azide  cycloaddition,  which  meant  that  all  the 
molecules added in the final reaction needed to have an alkyne terminus. Some of 
the reagents used in the last step were commercial and some of them had to be 
prepared in the laboratory.
All in all the synthetic process consisted of eight steps to prepare the scaffold and 
then  one  last  step  to  add the  functional  group.  Finally,  five  end products  were 
prepared. The more detailed explanations of reaction mechanisms are described in 
the following chapters. 
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3.1 Esterification
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Figure 2. Formation of acyl chloride. (12 p. 295, modified)
2-hydroxyproline is first converted into an acyl halide using thionyl chloride. The 
carboxylic acid has a bad leaving group OH-. In this reaction, it is turned into a 
good leaving group using a thionyl chloride, SOCl2. Carboxylic acid attacks thionyl 
chloride forming HCl and an unstable intermediate that is highly electrophilic. The 
intermediate  is  protonated  with  HCl  giving  an  electrophile  that  reacts  with  Cl- 
forming  again  an  unstable  intermediate.  This  intermediate  finally  collapses  into 
acyl chloride, SO2 and HCl. The reaction is irreversible because SO2 and HCl are 
gases  and  therefore  lost  from reaction  mixture.  (12  pp.  294-295)  The  reaction 
pathway for forming acyl chloride can be seen from Figure 2.
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VEM 2009 029
NH
OH
O
Cl
+ CH3OH
NH
OH
O
+
CH3
O
-
Cl
+ Cl
-
H
+
Figure 3. Esterification. (13 p. 300, modified)
Reaction is not ready yet since the acyl chloride still reacts. The methanol that is 
present in the reaction flask attacks the carbon atom at carbonyl group. This leads 
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to an unstable intermediate and finally to elimination of the chloride ion. (13 p. 
300) The amide function in the proline reacts with the free chloride ions forming a 
chlorine salt. The esterification reaction and the formed molecule VEM-2009-029 
are showed in Figure 3. 
3.2 Protecting groups
When dealing with multifunctional chemical compounds it is sometimes necessary 
to protect one or more of the functional groups in the molecule to prevent them to 
react causing unwanted products. There is a variety of different protecting groups 
designed for different purposes. When choosing a protecting group there are many 
things that need to be taken into consideration. (14 p.1)
The protecting group has to be specific to that functional group which it is going to 
protect.   The  reactions  that  are  performed  to  introduce  protecting  group and to 
cleave it should have a high yield and preferably be done without toxic chemicals. 
The protecting group should preferentially form a solid derivate, which is easy to 
purify. Protecting group should stay stable and not form new functional groups or 
affect the stereochemistry of the original compound. (14 p.1)
The BOC group
tert-Butyl  carbamate,  BOC group,  is  used  to  protect  amine  function  mainly  in 
peptide and heterocyclic syntheses. The BOC group is inert to many nucleophilic 
and electrophilic reagents and it does not hydrolyse easily in basic conditions. It can 
be  cleaved  using  only  strong  acid.  These  characteristics  make  it  a  popular 
protecting  group for  amines.  The  structure  of  tert-Butyl  carbamate  is  shown in 
Figure 4. (14, p.725)
16
O
O
Figure 4. The BOC group. (12 p.655)
Usually protecting groups are put on using a carbamoyl  chloride.  This does not 
work with BOC group because tert-BuOCOCl is too unstable. In this thesis work, 
the BOC group is put on using the anhydride BOC2O as it usually is the case. The 
structure of BOC2O can be seen in Figure 12 above the reaction arrow. (12 p. 655)
3.3 Mesylation
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Figure 5. Mesylation. (12 p. 486, modified)
The BOC protected compound has still one hydroxyl group. It is converted to mesyl 
group to make a better leaving group for the next step. Methanesulphonyl chloride 
reacts  with  alcohols  giving  methanesulphonate  esters  if  there  is  a  base  present 
(triethylamine  in this reaction).  First,  the base reacts  with the methanesulphonyl 
chloride so that an HCl molecule is eliminated. Then the formed sulphene reacts 
with the hydroxyl group forming the mesylate. The reaction mechanism can be seen 
in Figure 5. (12 pp. 485-486)
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3.4 Replacing a mesyl group with an azide group
N
O
O
OO O
S
O
O
N-
N
+
N
-
N O
OO O
N
N
+N
-
+ SO
O
-
OH
Figure 6. Replacing a mesyl group with an azide group. (12 p. 437, modified)
The azide molecule is a rod-shaped, linear molecule that is nucleophilic at both 
ends.  That  makes  it  able  to  insert  itself  into  almost  any electrophilic  site.  The 
nucleophilic  end  attacks  the  mesylated  carbon  forming  an  alkyl  azide  and 
eliminating the mesyl group. The reaction mechanism can be seen in Figure 6.
3.5 Hydrolysis of a methyl ester
N O
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Figure 7. Hydrolysis of a methyl ester. (12 p. 291, modified)
The esterificated carboxylic acid needs to be converted back to acid because in the 
next step it is coupled with a pyrrolidine ring. Hydrolysis  is done using a base, 
potassium hydroxide.  The hydroxyl  ion attacks the carbon atom in the carboxyl 
group and forms a carboxylic acid. For reaction mechanism see Figure 7.
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3.6 Coupling with O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
tetrafluoroborate
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Figure 8. Coupling of a pyrrolidine ring using TBTU.
The hydroxyl group of the carboxylic acid reacts with the electron positive carbon 
of  O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium  tetrafluoroborate  (TBTU) 
molecule forming a bond. The bond between carbon and oxygen is broken giving 
an extra electron to oxygen. This electronegative oxygen then attaches to carbonyl 
group. Being a  good leaving group, this  group makes  the carbonyl  group more 
accessible to the pyrrolidine ring. For reaction mechanism see Figure 8. 
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3.7 Removal of the di-tert-butyl dicarbonate protecting group
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Figure 9. Removal of the BOC protecting group. (12 p. 655, modified)
BOC protection can be removed with acid, in this case trifluoroacetic acid, TFA, 
was  used.  TFA  is  used  to  protonate  the  oxygen  in  the  carbonyl  group.  The 
protonated oxygen then attacks  the hydrogen,  which leads to the loss of  t-butyl 
cation. The rest of the molecule then decarboxylates to an unprotected molecule. 
The reaction mechanism can be seen in Figure 9.
3.8 Addition of a phenylbutanoic group
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Figure 10. Addition of a phenylbutanoic group. (12 p. 284, modified)
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The  amine  was  deprotected  in  the  previous  step  to  make  it  accessible  for  the 
coupling reaction. The reaction is a simple reaction with the acyl chloride derived 
from phenylbutanoic acid to form an amide. The amine attacks the carbonyl carbon 
in the acyl chloride eliminating chloride ion. The reaction mechanism can be seen 
in Figure 10. In previous experiments with the PO inhibitors it  was noticed that 
positioning a phenylbutanoic group in this part of the inhibitor affected less with 
the inhibition rate of the molecule. That means that it was better to replace BOC 
protecting group with phenylbutanoic group so that the inhibition would be most 
effective. 
3.9 Copper-(I)-catalysed 1,3-dipolar addition
The CuI-catalysed 1,3-dipolar addition of an azide and an alkyne is used in this 
work to couple the scaffold and the functional group together in the last step of 
syntheses. It is classified as “click chemistry”,  a relatively new group of synthetic 
methods. Click chemistry has gotten its name from the fact that the reactions are 
fast  and  they  require  only  benign  reaction  conditions  and  simple  work-up  and 
purification procedures. The mechanism of the copper(I) catalysed version of this 
reaction has only partially been unravelled. (15)
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4 METHODS AND INSTRUMENTATION OF LABORATORY 
EXPERIMENTS
4.1 Flash chromatography
Flash chromatography is a purification method. It is similar to traditional column 
chromatography but it is done under a pressure to speed up the elution time. The 
sample that is to be purified is placed on a top of a column usually filled with silica 
(normal phase). (16 p. 179) Sample can be either dissolved in a small amount of 
toluene or attached to silica or kieselguhr. The column is then attached to the pump 
and the elution is performed. The product and impurities are collected into tubes. 
From every collected tube, a small sample is applied to a TLC plate. The plate and 
MS are then used to detect the tubes with the pure compound. 
With this method, the separation quality is not the best but it is faster than many 
other methods. One run could be something from 10 minutes to  a couple of hours. 
In this work, the purifications that were made took about half an hour.  This method 
works best for samples that have only few components. (16 p. 179)
In this work, some of the compounds were purified using column chromatography. 
A glass column is filled with silica and the silica-bound sample is added to the top. 
The elution flow can be forced to go faster by pumping air to the column.
4.2 Thin layer chromatography and preparative TLC
Thin layer chromatography (TLC) is a fast and practical way of following the flow 
of syntheses.  It is usually done using plastic,  aluminium or glass plates covered 
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with  silica  (SiO2)  or  alumina  (Al2O3)  (16  p.  256).  The  materials  for  TLC  are 
affordable and the work process is easy to learn. That is why it is so commonly 
used in  organic  chemistry to  examine  the reaction  process.  In these reactions  a 
common UV active  TLC-plate  was used and UV light  and ninhydrin  colouring 
were used for detection.
Preparative TLC is an ordinary TLC scaled up. It is an analytical technique that can 
also be used to  isolate  compounds.  The adsorbent  layer,  usually silica,  is  much 
thicker (0.5-2.0 mm) and the plate itself is larger (12x12 inch) (17 p. 276). With 
one plate a large amount, 10 - 100 mg, of product can be purified. The product is 
applied to the plate as a streak 1 cm from the bottom and 2 cm from the edges. The 
width of the streak depends on how much product there is to be purified. Same 
plate can be used for multiple products if there is enough space. After the plate is 
developed, the right band can be scraped off and then product is separated from the 
adsorbent with suitable solvent. (17 p. 80)
23
5 SYNTHESES
5.1 Esterification
N
H
OH
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OH
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O
Cl Cl
NH2
+
OH
O
OCl
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α
βγ
δ
VEM 2009 029
Figure 11. Synthesis of VEM-2009-029.
A 500 ml round bottomed flask was filled with argon through a rubber septum. The 
flask was then charged with dry methanol  (150 ml)  and cooled in  an ice bath. 
Sulphurous dichloride (12.45 ml, 172 mmol) was added to methanol carefully. 2-
hydroxyproline  (15 g,  114 mmol)  was added to  the solution.  The ice  bath was 
removed and the solution was allowed to warm up to room temperature. Then the 
solution was heated to 70 °C with a reflux condenser and refluxed for 2 hours. 
Methanol was evaporated and the crude product was precipitated and washed with 
ether. The starting material and the final product are drawn in Figure 11. For NMR 
and MS spectra of the product see Appendix 1. 
Yield: 92 %
ES-MS: m/z 146.1 = [M+H]+
1H NMR (D2O, 400 MHz) δ: 2.0 (1H, m, β1), 2.2 (1H, m, β2), 3.1 (1H, d, δ1), 3.2 
(1H, m, δ2), 3.5 (3H, s, CH3), 4.4 (H2O and underneath it α and γ)
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5.2 Di-tert-butyl dicarbonate protection
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VEM 2009 030
Figure 12. Synthesis of VEM-2009-030.
VEM-2009-029 (19 g, 105 mmol) was dissolved in dichloromethane (DCM, 200 
ml) and cooled in an ice bath. Triethylamine (43.5 ml, 314 mmol) was added. Di-
tert-butyl dicarbonate (22.83 g, 105 mmol) was dissolved in DCM (50 ml) and the 
mixture was added to the reaction solution dropwise. The ice bath was removed and 
the reaction was stirred for overnight. DCM was evaporated and the residue was 
dissolved in ethyl acetate (EtOAc, 150 ml). The solution was washed with 1 M HCl 
(2×75  ml),  dried  over  sodium  sulphate,  filtered  and  evaporated  under  reduced 
pressure. The starting material and the final product are drawn in Figure 12. For 
NMR and MS spectra of the product see Appendix 2. 
Yield: 80 %. 
ES-MS: m/z 513.1 = [2M+Na]+, m/z 268.1 = [M+Na]+
1H NMR (CDCl3, 400 MHz) δ: 1.1 (9H, s, BOC), 1.8 (1H, m, β1), 2.0 (1H, m, β2), 
3.3 (2H, m, δ), 3.4 (3H, s, CH3), 4.1-4.2 (2H, m, γ+α)
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5.3 Mesylation
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VEM 2009 031
Figure 13. Synthesis of VEM-2009-031.
VEM-2009-030 (20 g, 82 mmol) was dissolved in DCM (100 ml) and triethylamine 
(16.73 ml,  122 mmol) was added. Solution was cooled in an ice bath.  Methane 
sulphonyl  chloride (6.94 ml,  90 mmol)  was dissolved in DCM (50 ml)  and the 
mixture was added to the reaction solution dropwise. The ice bath was removed and 
the solution was stirred for 2 hours.  DCM was evaporated and the residue was 
dissolved in EtOAc (150 ml). The solution was washed with 1 M HCl (2×75 ml), 
dried  over  sodium  sulphate,  filtered  and  evaporated  under  reduced  pressure. 
Product was dissolved in EtOAc and then precipitated with hexane,  filtered and 
washed with hexane. The starting material and final product are drawn in the Figure 
13. For NMR and MS spectra of the product see Appendix 3. 
Yield: 92 %
ES-MS: m/z 669.1 = [2M+Na]+, m/z 346.2 = [M+Na]+
1H NMR (CDCl3, 400 MHz) δ: 1.1 (9H, m, BOC), 2.0 (1H, m, β1), 2.3 (1H, m, β2), 
2.7 (3H, s, SCH3), 3.2 (2H, s, δ), 3.5 (3H, s, OCH3), 4.1 (1H, m, α), 5.0 (1H, s, γ)
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5.4 Converting a mesyl group to an azide group
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δ
VEM 2009 032
Figure 14. Synthesis of VEM-2009-032.
VEM-2009-031 (24 g, 74.2 mmol) was dissolved in dimethylformamide (70 ml). 
Sodium azide (9.65 g, 148 mmol) was added and the solution was heated to 85 °C. 
The solution was stirred for 3.5 hours at 85 °C. The reaction solution was dissolved 
in EtOAc (200 ml).  The solution was washed with H2O (2×150 ml),  dried over 
sodium sulphate,  filtrated  and  evaporated  under  reduced  pressure.  The  starting 
material and final product are drawn in Figure 14.  For NMR and MS spectra of the 
product see Appendix 4. 
Yield: 95 %.
ES-MS: m/z 563.1 = [2M+Na]+, m/z 293.1 = [M+Na]+
1H NMR (CDCl3, 400 MHz) δ: 1.1 (9H, d, BOC), 1.9 (1H, m, β1), 2.2 (1H, m, β2), 
3.2 (2H, s, δ), 3.4 (3H, s, CH3), 3.8 (1H, m, α), 4.0-4-1 (1H, m, γ)
5.5 Hydrolysis of a methyl ester 
N O
OO O
N3
N O
O O
N3
OH
KOH
VEM 2009 033
α
βγ
δ
Figure 15. Synthesis of VEM-2009-033.
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VEM-2009-032 (19 g, 70.3 mmol) was dissolved in methanol (20 ml). Potassium 
hydroxide  (1  M  solution  in  methanol,  70.3  ml,  70.3  mmol)  was  added  to  the 
solution which was then stirred for 28 h. Methanol was evaporated under reduced 
pressure. The residue was dissolved in water (75 ml) and washed with ether (50 
ml). The water layer was acidified with 2 M HCl to pH 1 and then extracted with 
EtOAc (3×100 ml). The combined organic layers were dried over sodium sulphate, 
filtrated and evaporated under reduced pressure. The starting material and the final 
product are drawn in Figure 15.  For NMR and MS spectra  of the product see 
Appendix 5. 
Yield: 79 %.
ES-MS: m/z 535.1 = [2M+Na]+, m/z 279.1 = [M+Na]+
1H NMR (CDCl3 + TMS, 400 MHz) δ: 1.5 (9H, d, BOC), 2.1-2.5 (2H, m,  β), 3.5 
(2H, s, δ), 4.1 (1H, m, α), 4.4 (1H, m, γ), 6.5 (1H, s, OH)
5.6 Coupling of a pyrrolidine ring using O-(benzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium tetrafluoroborate
      
Figure 16. Synthesis of VEM-2009-034.
VEM-2009-033 (14 g, 54.6 mmol) was dissolved in DCM (100 ml) together with 
triethylamine (19.06 ml, 137 mmol). TBTU (14.63 g, 45.7 mmol) and pyrrolidine 
(3.75 ml, 45.7 mmol) were added and the reaction was stirred overnight. DCM was 
evaporated and the crude product was redissolved in EtOAc and washed with H2O, 
saturated NaHCO3 and saturated NaCl. The organic layer was dried over sodium 
28
sulphate, filtered and evaporated under reduced pressure. The crude product was 
purified using column chromatography (gradient: hexane to EtOAc) yielding white 
crystalline mass. The starting material and the final product are drawn in Figure 16. 
For NMR and MS spectra of the product see Appendix 6. 
Yield: 65 %.
ES-MS: m/z 641.2 = [2M+Na]+, m/z 332.2 = [M+Na]+
1H NMR (CDCl3, 400 MHz)  δ: 1.1 (9H, d, BOC), 1.5-1.7 (3H, m,  β’+β), 3.0-3.2 
(4H, m, α’), 3.4-3-6 (2H, m, δ), 3.7 (1H, m, α), 4.1-4.2 (1H, m, γ)
5.7 Removal the di-tert-butyl dicarbonate protecting group 
Figure 17. Synthesis of VEM-2009-035.
VEM-2009-034  (9.22  g,  29.8  mmol)  was  dissolved  in  DCM  (90  ml)  and 
trifluoroacetic acid (TFA, 90 ml, 1168 mmol) was added. The reaction was stirred 
for 30 minutes and then the volatiles were evaporated under reduced pressure. Most 
of the TFA was co-evaporated  with hexane.  The starting material  and the final 
product  are  drawn in  Figure  17.  For  NMR and MS spectra  of  the  product  see 
Appendix 7. 
Yield: 195 % (TFA forms a salt with the product and it is hard to get rid of. Yield 
of 150 % to 200 % is usually considered acceptable.)
ES-MS: m/z 419.3 = [2M+H]+, m/z 210.2 = [M+Na]+
1H NMR (CDCl3, 400 MHz) δ: 1.6-1.8 (6H, m, β+β’), 2.5 (4H, m, α’), 3.2 (2H, m, 
δ), 3.4 (1H, m, α), 4.2-4.4 (1H, m, γ), 8.8 (1H, s, NH)
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5.8 Addition of a phenylbutanoic group 
Figure 18. Synthesis of VEM-2009-037.
VEM-2009-035  (9.13  g,  29.8  mmol)  was  dissolved  in  DCM  (75  ml)  and 
triethylamine (12.39 ml, 89 mmol) was added. The solution was cooled in a water 
bath. 4-phenylbutanoyl chloride (5.44 g, 29.8 mmol) was dissolved in DCM (5 ml) 
and added to the solution dropwise. The solution was stirred for 1h 30 minutes. The 
solution  was  washed  with  1  M  HCl,  dried  over  sodium  sulphate,  filtered  and 
evaporated under reduced pressure. The crude product was purified using column 
chromatography (gradient: hexane to EtOAc) yielding white crystalline mass. The 
starting material and the final product are drawn in Figure 18. For NMR and MS 
spectra of the product see Appendix 8. 
Yield: 43 %.
ES-MS: m/z 733.1 = [2M+Na]+, m/z 378 = [M+Na]+, m/z 356.2 = [M+H]+
1H NMR (MEOD, 400 MHz)  δ: 1.6 (4H, m,  β’) 1.7 (2H, m, CH2), 2.1 (2H, m, 
CH2), 2.4 (4H, m, α’), 3.0 (2H, m, CH2), 3.1 (2H, m, CH2), 3.2 (2H, m, β), 3.9 
(1H, m, α), 4.3 (1H, t, γ), 6.8-7.0 (5H, m, Ar)
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5.9 Introduction of an imidazole substituent
Figure 19. Synthesis of VEM-2009-047.
VEM-2009-037  (454  mg,  1.277  mmol)  was  dissolved  in  methanol  (5  ml).  5-
ethynyl-1-methyl-1H-imidazole  (excess)  and  copper(I)iodide  (catalytic  amount) 
were added. The solution was stirred over weekend. Methanol was evaporated and 
the product was purified with column chromatography (gradient: hexane to EtOAc: 
20%  methanol)  and  preparative  TLC  plate  (eluent:  DCM:  5%  methanol).  The 
starting  material  and  final  product  are  drawn in  Figure  19.  For  NMR and MS 
spectra together with HPLC chromatogram of the product see Appendix 9. 
Yield: 5 %
Purity: 100 %
ES-MS: m/z 462.20 = [M+H]+, m/z 484.1 = [M+Na]+, m/z 500.3 = [M+K]+
1H NMR (CDCl3+TMS, 400 MHz)  δ: 1.2 (2H, m, β’1), 1.9 (4H, m, CH2×2), 2.3 
(2H, m, β’2), 2.7 (2H, m, CH2), 3.1 (2H, t, β), 3.5 (2H, m, CH2N), 3.8 (1H, m, α’1), 
4.0-4.3 (3H, m, α’2,3,4), 4.5-5.0 (2H, m, δ), 5.1 (1H, t, α), 5.5 (1H, s, γ), 6.3 (3H, s, 
CH3), 7.0-7.3 (5H, m, Ar), 8.7 (3H, s, triazole, 2 × imidazole)
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5.10 Introduction of a di-tert-butyl dicarbonate protected piperazine substituent
Figure 20. Synthesis of VEM-2009-041.
VEM-2009-037 (159 mg, 0.466 mmol) was dissolved in methanol (5 ml). tert-Butyl 
4-(prop-2-ynyl)piperazine-1-carboxylate  (excess)  and  copper(I)iodide  (catalytic 
amount)  were  added.  The  solution  was  stirred  over  weekend.  Methanol  was 
evaporated and the product was purified with column chromatography (gradient: 
hexane to EtOAc: 20% methanol). The starting material and the final product are 
drawn in Figure 20. For NMR and MS spectra together with HPLC chromatogram 
of the product see Appendix 10. 
Yield: 59 %
Purity: 99.65 %
ES-MS: m/z 602.4 = [2M+Na]+, m/z 580.4 = [M+Na]+
1H NMR (CDCl3, 400 MHz)  δ: 1.5 (9H, s, BOC), 1.9 (2H, m,  β’1), 2.0 (2H, m, 
CH2), 2.3 (2H, m, CH2), 2.5 (2H, m, β’2), 2.7 (2H, m, CH2), 2.9 (2H, s, β), 3.4 (4H, 
m, α’1 + α’2), 3.4 - 4.0 (8H, m, piperazine), 3.9 (1H, m, δ1), 4.2 (1H, m, δ2), 4.8 
(1H, t, α), 5.4 (1H, s, γ), 7.1-7.3 (5H, m, Ar), 8.0 (1H, s, triazole)
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5.11 Introduction of a morpholine substituent
Figure 21. Synthesis of VEM-2009-043.
VEM-2009-037 (170 mg, 0.478 mmol) was dissolved in methanol (5 ml). 4-(Prop-
2-ynyl)morpholine  (excess)  and  copper(I)iodide  (catalytic  amount)  were  added. 
The solution was stirred over weekend. Methanol was evaporated and the product 
was  purified  with  column  chromatography  (gradient:  hexane  to  EtOAc:  20% 
methanol). The starting material and the final product are drawn in Figure 21. For 
NMR  and  MS  spectra  together  with  HPLC  chromatogram  of  the  product  see 
Appendix 11. 
Yield: 75 %
Purity: 100 %
ES-MS: m/z 503.2 = [M+Na]+, m/z 481.3 = [M+H]+
1H NMR (CDCl3+TMS, 400 MHz) δ: 1.9 (2H, m, β’1), 2.0 (2H, m, CH2), 2.3 (2H, 
m, CH2), 2.4 (2H, m, β’2), 2.6 (2H, m, CH2), 2.9 (2H, s, β), 3.4 (2H, m, α’1), 3.5 
(2H, m, α’2), 3.7-4.0 (9H, m, morpholine + δ1), 4.2 (1H, s, δ2), 4.8 (1H, t, α), 5.4 
(1H, t, γ), 7.1-7.3 (5H, m, Ar), 8.0 (1H, s, triazole)
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5.12 Introduction of a BOC protected amine substituent
Figure 22. Synthesis of VEM-2009-045.
VEM-2009-037 (744 mg, 2.093 mmol) was dissolved in methanol (5 ml). tert-Butyl 
prop-2-ynylcarbamate (excess) and copper(I)iodide (catalytic amount) were added. 
The solution was stirred over weekend. Triethylamine was added to catalyse the 
reaction and the reaction was stirred overnight. Methanol was evaporated and  the 
product was purified with column chromatography (gradient:  hexane to EtOAc). 
The starting material and the final product are drawn in Figure 22. For NMR and 
MS spectra together with HPLC chromatogram of the product see Appendix 12. 
Yield: 75 %
ES-MS: m/z 612.3 = [M+TEA]+, m/z 533.3 = [M+Na]+
1H NMR (CDCl3+TMS, 400 MHz) δ: 1.4 (9H, s, BOC), 1.8 (2H, m, β’1+β’2), 2.0 
(2H, m, CH1), 2.3 (2H, m, CH2), 2.4 (1H, m, β’3), 2.6 (2H, m, CH2), 2.8 (1H, m, 
β’), 3.4 (4H, m,  β1, NH, CH2), 3.5 (1H, m,  β2), 3.9 (2H, m,  α’1+2), 4.1 (1H, t, 
α’3), 4.4 (3H, d,  α’4,  δ1+2), 4.7 (1H, t,  δ3), 5.2 (1H, t,  α), 5.4 (1H, s,  γ), 7.1-7.3 
(5H, m, Ar), 7.8 (1H, s, triazole)
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5.13 Removal of  the BOC protecting group 
Figure 23. Synthesis of VEM-2009-046.
VEM-2009-045  (680  mg,  1.332  mmol)  was  dissolved  in  DCM  (5  ml).  2,2,2-
Trifluoroacetic acid (5 ml, 64.9 mmol) was added. The reaction was stirred for 1h 
30 minutes. Then the volatiles were evaporated under reduced pressure. TFA is co-
evaporated with hexane. The product was dissolved in methanol and 5-6 N HCl in 
2-propanol was added. The volatiles were evaporated and the product was washed 
with ether. The starting material and the final product are drawn in Figure 23. For 
NMR  and  MS  spectra  together  with  HPLC  chromatogram  of  the  product  see 
Appendix 13. 
Yield: 97 %
Purity: 100 %
ES-MS: m/z 411.3 = [M]+, m/z 434.3 = [M+Na]+, m/z 821.1 = [2M]+
1H NMR (CDCl3+TMS, 400 MHz)  δ: 1.2 (2H, m,  β’1), 1.9 (4H, m, CH2×2), 2.3 
(2H, m, β’2), 2.5 (2H, m, CH2), 3.1 (2H, t, β), 3.4 (2H, m, CH2N), 3.8 (1H, m, α’1), 
4.0-4.3 (3H, m, α’2,3,4), 4.5-5.0 (2H, m, δ), 5.1 (1H, t, α), 5.5 (1H, s, γ), 6.3 (2H, s, 
NH2), 7.0-7.3 (5H, m, Ar), 8.7 (1H, s, triazole) 
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6 DISCUSSION
The purification of the products was challenging. In many of the products there was 
seen a small peak just next to the products signal. This means that the retention time 
of impurity is very close to the products and this makes purification difficult. This 
could be  a  result  of  different  configurations  that  are  formed  in  the  last  step  of 
synthesis.  Even  though  the  exact  mechanism  of  the  copper-(I)-catalysed  1,2,3-
triazole  introduction is not fully understood there are some details that are more or 
less certain. That is, it can be predicted that the molecule that is added to the azide 
ring attaches itself to the carbon that is further away from the rest of the molecule. 
However, there still is a possibility that it is attached to the other carbon and this 
could be impurity that is formed. It could explain why it has so similar retention 
time. 
This problem might be prevented by modification of reaction conditions. Also a 
better purification method would help with this problem. Flash chromatography is 
not accurate enough but for example a preparative HPLC could solve the problem.
Beginner’s clumsiness can be seen from the NMR spectra. In some spectra (VEM-
2009-033 for example), the TMS peak is too strong. In some samples there may 
have been too much solvent which could explain the widened peaks. It has to be 
taken consideration also that the produced products were not pure enough. Some of 
the products were later purified even more but it was done in a later phase when the 
testing of the compounds were started.
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The synthesis has many steps which is not preferable. The more steps and phases 
the more impurities. It affects also the total yield. Maybe in this process the some 
steps could be somehow avoided or replaced. For example is it really necessary to 
first do the esterification and then hydrolyse again or could it be possible to just 
couple the pyrrolidine ring. 
The yields of single steps could also be improved. Maybe with different reaction 
conditions  some  reactions  could  work  better.  For  example  the  yields  for  click 
chemistry vary a lot. Of course the molecule and the amount of purification needed 
affects the result. Still, there are other ways for performing the click reactions than 
the above mentioned. Even small changes such as heating or adding a base could 
improve the yield. On the other hand it could also increase the amount of impurities 
or lead to unwanted reactions.
Should the development of these molecules into drugs become relevant all these 
aspects has to be taken into consideration. The inhibition activity of the prepared 
compounds is not yet  known. The testing itself is a simple process that is done 
using  a  photospectrometric  competition  assay of  prepared  inhibitors  with  a  PO 
substrate in the presence of the target enzyme. The results of the inhibitory activity 
was planned to be included in this thesis work but due to time limitations they had 
to be left out. 
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